Eugene Mutimura1, Diane Addison, Kathryn Anastos, Donald Hoover, Jean Claude Dusingize, Ben Karenzie, Isabelle Izimukwiye, Leo Mutesa, Sabin Nsanzimana, Denis Nash. 1. aRegional Alliance for Sustainable Development, Kigali, Rwanda bCUNY School of Public Health, New York cAlbert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York dThe State University of New Jersey, New Brunswick, New Jersey, USA eRwanda Military Hospital, Kigali fMasaka District Hospital, Kigali gCollege of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda hInstitute of HIV/AIDS and Disease Prevention and Control, Rwanda Biomedical Center Kigali, Rwanda iCUNY School of Public Health and Hunter College, New York, New York, USA.
Abstract
BACKGROUND: Initiation of antiretroviral therapy (ART) in the advanced stages of HIV infection remains a major challenge in sub-Saharan Africa. This study was conducted to better understand barriers and enablers to timely ART initiation in Rwanda where ART coverage is high and national ART eligibility guidelines first expanded in 2007-2008. METHODS: Using data on 6326 patients (≥15 years) at five Rwandan clinics, we assessed trends and correlates of CD4 cell count at ART initiation and the proportion initiating ART with advanced HIV disease (CD4 <200 cells/μl or WHO stage IV). RESULTS: Out of 6326 patients, 4486 enrolling in HIV care initiated ART with median CD4 cell count of 211 cells/μl [interquartile range: 131-300]. Median CD4 cell counts at ART initiation increased from 183 cells/μl in 2007 to 293 cells/μl in 2011-2012, and the proportion with advanced HIV disease decreased from 66.2 to 29.4%. Factors associated with a higher odds of advanced HIV disease at ART initiation were male sex [adjusted odds ratios (AOR) = 1.7; 95% confidence interval (CI): 1.3-2.1] and older age (AOR46-55+vs.<25 = 2.3; 95% CI: 1.2-4.3). Among those initiating ART more than 1 year after enrollment in care, those who had a gap in care of 12 or more months prior to ART initiation had higher odds of advanced HIV disease (AOR = 5.2; 95% CI: 1.2-21.1). CONCLUSION: Marked improvements in the median CD4 cell count at ART initiation and proportion initiating ART with advanced HIV disease were observed following the expansion of ART eligibility criteria in Rwanda. However, sex disparities in late treatment initiation persisted through 2011-2012, and appeared to be driven by later diagnosis and/or delayed linkage to care among men.
BACKGROUND: Initiation of antiretroviral therapy (ART) in the advanced stages of HIV infection remains a major challenge in sub-Saharan Africa. This study was conducted to better understand barriers and enablers to timely ART initiation in Rwanda where ART coverage is high and national ART eligibility guidelines first expanded in 2007-2008. METHODS: Using data on 6326 patients (≥15 years) at five Rwandan clinics, we assessed trends and correlates of CD4 cell count at ART initiation and the proportion initiating ART with advanced HIV disease (CD4 <200 cells/μl or WHO stage IV). RESULTS: Out of 6326 patients, 4486 enrolling in HIV care initiated ART with median CD4 cell count of 211 cells/μl [interquartile range: 131-300]. Median CD4 cell counts at ART initiation increased from 183 cells/μl in 2007 to 293 cells/μl in 2011-2012, and the proportion with advanced HIV disease decreased from 66.2 to 29.4%. Factors associated with a higher odds of advanced HIV disease at ART initiation were male sex [adjusted odds ratios (AOR) = 1.7; 95% confidence interval (CI): 1.3-2.1] and older age (AOR46-55+vs.<25 = 2.3; 95% CI: 1.2-4.3). Among those initiating ART more than 1 year after enrollment in care, those who had a gap in care of 12 or more months prior to ART initiation had higher odds of advanced HIV disease (AOR = 5.2; 95% CI: 1.2-21.1). CONCLUSION: Marked improvements in the median CD4 cell count at ART initiation and proportion initiating ART with advanced HIV disease were observed following the expansion of ART eligibility criteria in Rwanda. However, sex disparities in late treatment initiation persisted through 2011-2012, and appeared to be driven by later diagnosis and/or delayed linkage to care among men.
Authors: Claudia Hawkins; Guerino Chalamilla; James Okuma; Donna Spiegelman; Ellen Hertzmark; Eric Aris; Tarcila Ewald; Ferdinand Mugusi; Deo Mtasiwa; Wafaie Fawzi Journal: AIDS Date: 2011-06-01 Impact factor: 4.177
Authors: Arif Alibhai; Walter Kipp; L Duncan Saunders; Ambikaipakan Senthilselvan; Amy Kaler; Stan Houston; Joseph Konde-Lule; Joa Okech-Ojony; Tom Rubaale Journal: Int J Womens Health Date: 2010-08-09
Authors: Riitta A Dlodlo; Paula I Fujiwara; Zanele E Hwalima; Stanley Mungofa; Anthony D Harries Journal: J Int AIDS Soc Date: 2011-07-06 Impact factor: 5.396
Authors: Kathrin Zürcher; Anne Mooser; Nanina Anderegg; Olga Tymejczyk; Margaret J Couvillon; Denis Nash; Matthias Egger Journal: Trop Med Int Health Date: 2017-02-20 Impact factor: 2.622
Authors: Min Jung Kim; Hyun Ha Chang; Sang Il Kim; Youn Jeong Kim; Dae Won Park; Chun Kang; Mee Kyung Kee; Ju Yeon Choi; Soo Min Kim; Bo Youl Choi; Woo Joo Kim; June Myung Kim; Jun Yong Choi; Young Hwa Choi; Jin Soo Lee; Shin Woo Kim Journal: Infect Chemother Date: 2017-06-01
Authors: Marco Gelpi; Hans J Hartling; Per M Ueland; Henrik Ullum; Marius Trøseid; Susanne D Nielsen Journal: BMC Infect Dis Date: 2017-05-16 Impact factor: 3.090